197 related articles for article (PubMed ID: 16369975)
1. Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy.
Rosário Cavalheiro Rde C; Vicari P; Maria Morselli F; Ommati LV; Frazão Rosa Fde O; Rodrigues Oliveira JS
Am J Hematol; 2006 Jan; 81(1):76-7. PubMed ID: 16369975
[No Abstract] [Full Text] [Related]
2. Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.
Okabe S; Tauchi T; Ishii Y; Akahane D; Nunoda K; Honda S; Takaku T; Ohyashiki K
Int J Hematol; 2007 Feb; 85(2):173-4. PubMed ID: 17321998
[No Abstract] [Full Text] [Related]
3. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
Beyazit Y; Aksu S; Kekilli M; Haznedaroglu IC; Kilickap S; Goker H
Am J Hematol; 2005 May; 79(1):79-80. PubMed ID: 15849758
[No Abstract] [Full Text] [Related]
4. Monolateral renal infarction and erythromelalgia in a case of chronic myelogenous leukemia.
Bernardini K; Lanthaler AJ; Buratti T; Mitterer M
Am J Hematol; 2006 Mar; 81(3):224-5. PubMed ID: 16493606
[No Abstract] [Full Text] [Related]
5. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
Machaczka M; Gossart M
Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191
[No Abstract] [Full Text] [Related]
6. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
Ito K; Tominaga K; Suzuki T; Jinnai I; Bessho M
Int J Hematol; 2005 Apr; 81(3):242-5. PubMed ID: 15814335
[TBL] [Abstract][Full Text] [Related]
7. New drug targets genetic malfunction in chronic myeloid leukemia.
Am J Health Syst Pharm; 2001 Jul; 58(14):1282. PubMed ID: 11471471
[No Abstract] [Full Text] [Related]
8. Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).
Chrobák L; Voglová J
Acta Medica (Hradec Kralove); 2003; 46(3):85-9. PubMed ID: 14677715
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia: where do we go now?
Cortés JE
Clin Lymphoma Myeloma; 2009; 9 Suppl 4():S374-5. PubMed ID: 20007105
[No Abstract] [Full Text] [Related]
10. Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance.
Sohn SK; Moon JH; Cho YY; Chae YS; Kim JG; Lee KS; Hong SP; Kim SO
Leuk Lymphoma; 2007 Aug; 48(8):1659-61. PubMed ID: 17701605
[No Abstract] [Full Text] [Related]
11. Selective effect of imatinib on serum IgM in a patient with CML.
Nagasawa M; Mizutani S
Int J Hematol; 2004 Nov; 80(4):381-2. PubMed ID: 15615266
[No Abstract] [Full Text] [Related]
12. [Molecular response with triple therapy in patients with chronic myeloid leukemia].
López-Arroyo JL; Rico-Ramos HJ; Portillo-García ML
Rev Med Inst Mex Seguro Soc; 2014; 52(3):262-5. PubMed ID: 24878083
[TBL] [Abstract][Full Text] [Related]
13. [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].
Voglová J; Maisnar V; Beránek M; Chrobák L
Vnitr Lek; 2006 Sep; 52(9):819-22. PubMed ID: 17091608
[TBL] [Abstract][Full Text] [Related]
14. Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients.
Dora JM; Leie MA; Netto B; Fogliatto LM; Silla L; Torres F; Maia AL
Eur J Endocrinol; 2008 May; 158(5):771-2. PubMed ID: 18426838
[No Abstract] [Full Text] [Related]
15. Effects of lower dose of imatinib to CML patients.
Horikoshi A; Takei K; Sawada S
Leuk Res; 2003 Dec; 27(12):1167. PubMed ID: 12921957
[No Abstract] [Full Text] [Related]
16. Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission.
Alonci A; Allegra A; Russo S; Penna G; Bellomo G; D'Angelo A; Campo S; Cannavò A; Centorrino R; Musolino C
Acta Haematol; 2012; 127(1):1-6. PubMed ID: 21986252
[TBL] [Abstract][Full Text] [Related]
17. The Importance of Body Surface Area at Baseline and during Treatment in Chronic Myeloid Leukemia Patients Treated with Imatinib.
Breccia M; Molica M; Colafigli G; Alimena G
Acta Haematol; 2015; 134(1):57-8. PubMed ID: 25870940
[No Abstract] [Full Text] [Related]
18. Granulocytic sarcoma of the stomach: relapse after hematopoietic stem-cell transplantation for chronic myeloid leukemia.
Macedo AV; Freitas IF; Oliveira FB; Resende C; Mendes CU; Vieira AK; Castro LC; Rego EM; Clementino NC; Bittencourt H
Hematol Oncol Stem Cell Ther; 2010; 3(2):94-8. PubMed ID: 20543544
[TBL] [Abstract][Full Text] [Related]
19. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.
Marin D; Goldman JM; Olavarria E; Apperley JF
Blood; 2003 Oct; 102(7):2702-3; author reply 2703-4. PubMed ID: 14504074
[No Abstract] [Full Text] [Related]
20. Pregnancies in patients with chronic myeloid leukemia in the era of imatinib.
Koh LP; Kanagalingam D
Int J Hematol; 2006 Dec; 84(5):459-62. PubMed ID: 17189230
[No Abstract] [Full Text] [Related]
[Next] [New Search]
